Top

Published in:

01-05-2016 | Original Article

Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy

Authors: Neta Goldschmidt, Geffen Kleinstern, Marina Orevi, Ora Paltiel, Dina Ben-Yehuda, Alex Gural, Diana Libster, David Lavie, Moshe E Gatt

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2016

Abstract

Purpose

Outcomes in primary mediastinal B cell lymphoma (PMBL) improved with the introduction of dose intense treatments, consolidation radiotherapy and rituximab. DA-EPOCH-R, which omits radiotherapy has been adopted with worldwide enthusiasm, despite lack of proven superiority in randomized trials. We aimed to evaluate the course and outcome of PMBL using an alternative intensive rituximab-containing regimen, RCHOP-RICE. We also evaluated the prognostic value of ¹⁸FDG-PET-CT (PET-CT).

Methods

We reviewed the clinical, laboratory and imaging data of PMBL patients receiving 1st-line treatment in Hadassah Medical Center between 8/2002 and 10/2014.

Results

Of 47 PMBL patients, 24 (51 %) were treated with RCHOP-RICE and 23 (49 %) with other protocols. Overall, the 5-year progression-free survival was 93 % and the overall survival was 98 % (87 and 100 %, respectively, for the RCHOP-RICE regimen). Patient characteristics and treatment toxicities were balanced among protocols. A mean of 11.1 ± 1.3 hospitalization days/patient were needed to administer RCHOP-RICE regimen compared to 37 ± 2 days/patient for DA-EPOCH-R (n = 2). Radiotherapy was given to 3 patients (12 %) treated with RCHOP-RICE compared to 18 patients (78 %) treated with other protocols (p < 0.01). For patients followed with interim and end of treatment (EOT) PET-CT, we observed a significant reduction in the uptake between the two (p < 0.0001). Using a Deauville score cutoff of 3, the negative and positive predictive values (NPV and PPV) of EOT PET-CT were 94 and 33 %, respectively.

Conclusions

The RCHOP-RICE protocol results in excellent survival outcomes, generally permits omission of RT and is simpler to administer than DA-EPOCH-R. Interim PET-CT in PMBL may be unjustified; however, EOT Deauville scores ≤3 predicts a favorable outcome.

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019–5032CrossRefPubMedPubMedCentral

Martelli M, Ferreri AJM, Johnson P (2008) Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 68(3):256–263CrossRefPubMed

Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E et al (1993) Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol Off J Am Soc Clin Oncol 11(12):2306–2313

Dabrowska-Iwanicka A, Walewski JA (2014) Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep 9(3):273–283CrossRefPubMedPubMedCentral

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851–862CrossRefPubMedPubMedCentral

Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871–3879CrossRefPubMed

Lazzarino M, Orlandi E, Paulli M, Sträter J, Klersy C, Gianelli U et al (1997) Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol Off J Am Soc Clin Oncol 15(4):1646–1653

Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E et al (2001) Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 86(2):187–191PubMed

Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F et al (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 90(2):372–376CrossRefPubMedPubMedCentral

10.

Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J et al (2011) Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol Off J Eur Soc Med Oncol ESMO 22(3):664–670CrossRef

11.

Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E et al (2012) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 17(2):239–249CrossRefPubMedPubMedCentral

12.

Tai WM, Quah D, Yap SP, Tan SH, Tang T, Tay KW et al (2011) Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leuk Lymphoma 52(4):604–612CrossRefPubMed

13.

Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K et al (2014) Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica 99(12):1817–1825CrossRefPubMedPubMedCentral

14.

Savage KJ, Yenson PR, Shenkier T, Klasa R, Villa D, Goktepe O et al (2012) The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 120(21):303

15.

Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P et al (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 117(6):1806–1816CrossRefPubMedPubMedCentral

16.

Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD et al (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol Off J Eur Soc Med Oncol ESMO 17(1):123–130CrossRef

17.

Giri S, Bhatt VR, Pathak R, Bociek RG, Vose JM, Armitage JO (2015) Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis. Am J Hematol 90(11):1052–1054

18.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, et al. (2015) PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia 30:238–242

19.

Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D et al (2013) Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 87(2):311–316CrossRefPubMed

20.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJM, Vitolo U et al (2014) [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol Off J Am Soc Clin Oncol 32(17):1769–1775CrossRef

21.

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416CrossRefPubMedPubMedCentral

22.

Prahladan M, Grigoropoulos NF, Munisamy S, Hodson A, Shaw A, Wright P et al (2012) Interim PET scan does not predict outcome in primary mediastinal B cell lymphoma treated with R DA EPOCH. Blood 120(21):4846

23.

Woessmann W, Lisfeld J, Burkhardt B, NHL-BFM Study Group (2013) Therapy in primary mediastinal B-cell lymphoma. N Engl J Med 369(3):282CrossRefPubMed

24.

(1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329(14):987–994

25.

Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A (2014) Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma 55(1):31–37CrossRefPubMed

26.

Mounier N, Briere J, Gisselbrecht C, Emile J-F, Lederlin P, Sebban C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101(11):4279–4284CrossRefPubMed

27.

O’Reilly SE, Hoskins P, Klimo P, Connors JM (1991) MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin’s disease. Ann Oncol Off J Eur Soc Med Oncol ESMO 2(Suppl 1):17–23CrossRef

28.

Hagberg H, Gisselbrecht C, CORAL study group (2006) Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol Off J Eur Soc Med Oncol ESMO 17(Suppl 4):iv31–iv32CrossRef

29.

Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y et al (2014) The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 93(8):1297–1304CrossRefPubMed

30.

Ceriani L, Martelli M, Zinzani PL, Ferreri AJM, Botto B, Stelitano C et al (2015) Utility of baseline ¹⁸FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 126(8):950–956CrossRefPubMed

31.

Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH et al (2015) A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma 14:1–14CrossRef

32.

Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF et al (2015) Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113–121CrossRefPubMed

33.

Cheah CY, Hofman MS, Seymour JF, Ritchie DS, Dickinson M, Wirth A et al (2015) The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma 56(1):49–56CrossRefPubMed

34.

Vassilakopoulos TP, Pangalis GA, Polliack A (2015) A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma 56(1):3–5CrossRefPubMed

35.

Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD (2010) Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01–142) without radiotherapy for patients with primary mediastinal large B Cell lymphoma. Blood 116(21):420

Title: Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
Authors: Neta Goldschmidt
Geffen Kleinstern
Marina Orevi
Ora Paltiel
Dina Ben-Yehuda
Alex Gural
Diana Libster
David Lavie
Moshe E Gatt
Publication date: 01-05-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3024-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2016

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation

Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer

Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer